FGFR2 fusion-positive cholangiocarcinoma became one of the first biomarker-defined niches in bile duct cancer, and acquired resistance to reversible inhibitors emerged quickly. Lytgobi (futibatinib) took a covalent approach.
Futibatinib binds FGFR irreversibly and covalently, preserving activity against some resistance mutations that defeat reversible inhibitors. The once-daily tablet treats previously treated, unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Lytgobi’s accelerated approval remains ongoing, leaving its confirmatory trial obligation an open regulatory item. It holds orphan designation and competes with pemigatinib plus the niche infigratinib vacated, making resistance-mutation coverage the key differentiator.
